Registration Now Open for Ingram Micro’s Global ONE Experience – Join Us November 4-5 Online for an Unforgettable Event
7.10.2020 18:30:00 EEST | Business Wire | Press release
For the first time in its history, Ingram Micro Inc. is taking its ONE event to a fully global audience in a completely online interactive experience. Bringing together APAC ONE, EMEA ONE, LATAM ONE and North America ONE enable Ingram Micro to support multiple time zones and languages, while hosting 12 keynotes, 150 sessions and speakers and attendees from more than 60 countries.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201007005717/en/
“We’ve set high expectations, and are excited to have our partners and providers take what they hear, see and experience at ONE and imagine what’s next for their business, their partner ecosystem and their customers." Paul Bay, EVP and President, Global Technology Solutions, Ingram Micro Inc. (Graphic: Business Wire)
As part of the experience, localized content and sessions will be provided for each region. Targeted sessions will also be held pre- and post-experience for special guests attending by countries and communities including Ingram Micro’s SMB Alliance and Trust X Alliance. Ingram Micro channel partners and providers are encouraged to register now at https://imaginenext.ingrammicro.com/one.
Ingram Micro’s executive leadership team will kick off this year’s online experience starting with opening remarks from CEO Alain Monié and EVP and President Paul Bay. Additional event highlights include:
- Fireside chats with Cisco CEO Chuck Robbins and IBM President Jim Whitehurst
- Futurist keynote featuring 311 Institute Founder and CEO Matthew Griffin
- Diversity and Inclusion Keynote from Former NASA Space Science Education Lead Hakeem Oluseyi
- Technology and trends keynote from IDC Group Vice President Michelle Bailey
- Executive addresses from global business leaders including Ingram Micro’s SVP of Marketing Jennifer Anaya, EVP Global Cloud Nimesh Davé, and VP of Global Partner Engagement and IoT Sabine Howest
- Special guests including a GRAMMY award winning musician and bands from around the globe
- An inspired address from one of the best-selling authors, and optimistic motivational speakers on the planet
A complete list of speakers and sessions, including the identities of the above artists and motivational speaker, is noted here. Additionally, several key Ingram Micro announcements and strategic initiatives are expected to launch leading up to and throughout the event, including community announcements from SMB Alliance and Trust X Alliance. Live networking, virtual happy hours and AI-powered business matchups are also on tap for attendees.
“We’ve set high expectations, and are excited to have our partners and providers take what they hear, see and experience at ONE and imagine what’s next for their business, their partner ecosystem and their customers,” said Bay. “Together we are working smarter, harder and with a greater purpose. Ingram Micro and the ecosystem of partner excellence we support has never been more relevant to the vitality and success of today’s business landscape locally, regionally and globally…and we’re ready to do even more.”
Channel press and analysts are welcome to register and attend designated sessions of the Nov. 4-5 Ingram Micro ONE Experience.
For more information visit https://imaginenext.ingrammicro.com/one.
About Ingram Micro
Ingram Micro helps businesses realize the promise of technology. It delivers a full spectrum of global technology and supply chain services to businesses around the world. Deep expertise in technology solutions, mobility, cloud, and supply chain solutions enables its business partners to operate efficiently and successfully in the markets they serve. Unrivaled agility, deep market insights and the trust and dependability that come from decades of proven relationships, set Ingram Micro apart and ahead. Discover how Ingram Micro can help you realize the promise of technology. More at www.ingrammicro.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201007005717/en/
Contact information
Marie Rourke
WhiteFox Marketing
714.292.2199
marie@whitefoxpr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom